Terms ending in 2028
Every in-force patent on Allergan, Inc.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,645,460 | Dosage Forms of Risedronate In force · Medium confidence | Allergan Pharmaceuticals International Limited | In force | Medium confidence | |
| US 7,977,351 | Heteroaryl Dihydroindolones as Kinase Inhibitors In force · High confidence | Allergan, Inc. | In force | High confidence | |
| US 8,236,023 | Apparatus and Method for Volume Adjustment of Intragastric Balloons In force · High confidence | Boston Scientific Scimed, Inc. | In force | High confidence | |
| US 7,612,082 | Prostaglandin EP4 Antagonists In force · High confidence | Allergan, Inc. | In force | High confidence | |
| US 9,365,485 | Substituted Arylcyclopentenes as Therapeutic Agents In force · High confidence | Allergan, Inc. | In force | High confidence | |
| US 9,796,696 | Substituted Arylcyclopentenes as Therapeutic Agents In force · High confidence | Allergan, Inc. | In force | High confidence | |
| US 7,884,115 | Compositions Comprising Nb-Dnj, Ne-Dnj or D-Glucaro-Delta-Lactam and Their Uses for the Treatment of Pain and Other Neurological Condittions In force · High confidence | Allergan, Inc. | In force | High confidence | |
| US 8,039,496 | Therapeutic Compounds In force · Medium confidence | Allergan, Inc. | In force | Medium confidence | |
| US 9,326,877 | Apparatus and method for intragastric balloon with in situ adjustment means In force · High confidence | Boston Scientific Scimed, Inc. | In force | High confidence | |
| US 7,960,381 | Substituted Gamma Lactams as Therapeutic Agents In force · Medium confidence | Allergan, Inc. | In force | Medium confidence | |
| 67 more term ends in 2028 · Pro | |||||
10 of 77 patents shown. Soonest term end first, then patent number.
Pro members see all 77, including 48 expiring within the 18 months from Nov 22, 2026.
60 of these are in force and held by Allergan, Inc..
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.